GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhenomeX Inc (NAS:CELL) » Definitions » Beneish M-Score

PhenomeX (PhenomeX) Beneish M-Score : 1.69 (As of Apr. 27, 2024)


View and export this data going back to 2020. Start your Free Trial

What is PhenomeX Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 1.69 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for PhenomeX's Beneish M-Score or its related term are showing as below:

CELL' s Beneish M-Score Range Over the Past 10 Years
Min: -4.01   Med: -2.24   Max: 13.52
Current: 1.69

During the past 5 years, the highest Beneish M-Score of PhenomeX was 13.52. The lowest was -4.01. And the median was -2.24.


PhenomeX Beneish M-Score Historical Data

The historical data trend for PhenomeX's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhenomeX Beneish M-Score Chart

PhenomeX Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
- - -2.48 -2.24 -4.01

PhenomeX Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.53 -3.57 -4.01 13.52 1.69

Competitive Comparison of PhenomeX's Beneish M-Score

For the Biotechnology subindustry, PhenomeX's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PhenomeX's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhenomeX's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where PhenomeX's Beneish M-Score falls into.



PhenomeX Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of PhenomeX for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0221+0.528 * 1.0335+0.404 * 14.3196+0.892 * 0.8268+0.115 * 0.8127
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.7757+4.679 * -0.181504-0.327 * 1.263
=1.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun23) TTM:Last Year (Jun22) TTM:
Total Receivables was $14.86 Mil.
Revenue was 14.062 + 18.516 + 17.841 + 21.398 = $71.82 Mil.
Gross Profit was 6.043 + 13.428 + 12.003 + 15.025 = $46.50 Mil.
Total Current Assets was $94.79 Mil.
Total Assets was $178.33 Mil.
Property, Plant and Equipment(Net PPE) was $58.93 Mil.
Depreciation, Depletion and Amortization(DDA) was $14.43 Mil.
Selling, General, & Admin. Expense(SGA) was $110.10 Mil.
Total Current Liabilities was $42.23 Mil.
Long-Term Debt & Capital Lease Obligation was $23.95 Mil.
Net Income was -50.245 + -23.419 + -29.301 + -21.566 = $-124.53 Mil.
Non Operating Income was -19.699 + -2.302 + -2.492 + -1.302 = $-25.80 Mil.
Cash Flow from Operations was -19.864 + -19.553 + -10.036 + -16.915 = $-66.37 Mil.
Total Receivables was $17.58 Mil.
Revenue was 19.15 + 20.206 + 23.186 + 24.324 = $86.87 Mil.
Gross Profit was 12.926 + 13.827 + 15.959 + 15.413 = $58.13 Mil.
Total Current Assets was $192.47 Mil.
Total Assets was $248.71 Mil.
Property, Plant and Equipment(Net PPE) was $53.84 Mil.
Depreciation, Depletion and Amortization(DDA) was $10.25 Mil.
Selling, General, & Admin. Expense(SGA) was $74.99 Mil.
Total Current Liabilities was $29.14 Mil.
Long-Term Debt & Capital Lease Obligation was $43.93 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(14.855 / 71.817) / (17.58 / 86.866)
=0.206845 / 0.202381
=1.0221

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(58.125 / 86.866) / (46.499 / 71.817)
=0.669134 / 0.647465
=1.0335

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (94.786 + 58.934) / 178.332) / (1 - (192.47 + 53.839) / 248.706)
=0.138012 / 0.009638
=14.3196

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=71.817 / 86.866
=0.8268

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(10.246 / (10.246 + 53.839)) / (14.433 / (14.433 + 58.934))
=0.159881 / 0.196723
=0.8127

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(110.098 / 71.817) / (74.994 / 86.866)
=1.533035 / 0.86333
=1.7757

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((23.95 + 42.225) / 178.332) / ((43.931 + 29.138) / 248.706)
=0.371078 / 0.293797
=1.263

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-124.531 - -25.795 - -66.368) / 178.332
=-0.181504

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

PhenomeX has a M-score of 1.69 signals that the company is likely to be a manipulator.


PhenomeX Beneish M-Score Related Terms

Thank you for viewing the detailed overview of PhenomeX's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


PhenomeX (PhenomeX) Business Description

Traded in Other Exchanges
N/A
Address
5858 Horton Street, Suite 320, Emeryville, CA, USA, 94608
PhenomeX Inc is a functional cell biology company that provides live cell biology research tools which deliver deep insights into cellular function and new perspectives on phenomes.
Executives
Siddhartha Kadia director, officer: Chief Executive Officer 7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Mehul Joshi officer: Chief Financial Officer C/O BERKELEY LIGHTS, INC., 5858 HORTON STREET, SUITE 320, EMERYVILLE CA 94608
Peter Silvester director C/O BERKELEY LIGHTS, INC., 5858 HORTON STREET, SUITE 320, EMERYVILLE CA 94608
John R Chiminski director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Jessica Hopfield director C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Bird Mergersub Corp 10 percent owner 40 MANNING ROAD, BILLERICA MA 01821
Bruker Corp 10 percent owner 40 MANNING RD, BILLERICA MA 01821
James Paul Mcclaskey officer: SVP, Chief Accounting Officer C/O BERKELEY LIGHTS, INC., C/O BERKELEY LIGHTS, INC., EMERYVILLE CA 94608
Scott David Chaplin officer: Chief Legal Officer 3101 WILSON BOULEVARD, SUITE 700, ARLINGTON VA 22201
Eric Hobbs director, officer: Chief Executive Officer C/O BERKELEY LIGHTS, INC., 5858 HORTON STREET, SUITE 320, EMERYVILLE CA 94608
James Rothman director 135 EAST 83RD STREET, APT. 15C, NEW YORK NY 10028
Gregory T Lucier director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Keith Breinlinger officer: Chief Technical Officer C/O BERKELEY LIGHTS, INC., 5858 HORTON STREET, SUITE 320, EMERYVILLE CA 94608
Igor Y Khandros director, 10 percent owner 25 HACIENDAS ROAD, ORINDA CA 94563
Stuart L Merkadeau officer: General Counsel 7005 SOUTHFRONT ROAD, LIVERMORE CA 94551